H.C. Wainwright Reiterates Buy on Principia Biopharma, Raises Price Target to $63

H.C. Wainwright analyst Joseph Pantginis reiterates Principia Biopharma (NASDAQ:PRNB) with a Buy and raises the price target from $57 to $63.

Benzinga · 01/07/2020 16:36

H.C. Wainwright analyst Joseph Pantginis reiterates Principia Biopharma (NASDAQ:PRNB) with a Buy and raises the price target from $57 to $63.